Je was op zoek naar: obt (Engels - Maltees)

obt
obt

obt alone
waħedha

placebo + obt
karatteristika fil-linja bażi

obt (n = 237)
(n = 237)

genotypic ss in obt
ġenotipika f’ obt

obt alone n=209
kunfidenza 2) darbtejn kuljum + obt hiv- 1 rna

placebo + obt (n = 237)
(n = 237)

300 mg twice daily + obt
300 mg

genotypic sensitivity score in obt
punteġġ ta’ sensittività Ġenotipika għal obt

celsentri 300 mg twice daily + obt
300 mg

a median of 4 arts was used in obt.
fl-obt intuża medjan ta’ 4 arts.

adverse reactions or in combination with obt)
isentress (waħdu jew f’ kombinazzjoni ma ’ obt)

celsentri 300 mg twice daily + obt n=426
300 mg

400 mg twice daily + obt (n = 462)
400 mg darbtejn kuljum + obt (n = 462)

raltegravir400 mg twice daily + obt (n = 462)
raltegravir 400 mg darbtejn kuljum + obt

isentress (alone or in combination with obt) infections and infestations
isentress (waħdu jew f’ kombinazzjoni ma ’ obt)

key: 1gss to obt: genotypic sensitivity score to optimised background.
spjegazzjoni: 1gss għal obt: punteġġ ta’ sensittività Ġenotipika għall-aħjar kura fl-isfond (genotypic sensitivity score to optimised background).

isentress 400 mg b. i. d. + obt (n = 462)
b. i. d. + obt (n = 462)

enfuvirtide use in obt in enfuvirtide-naïve patients was counted as one active drug in obt.
l-użu ta’ enfuvirtide f’obt f’pazjenti li ma kinux ħadu enfuvirtide qabel ġie meqjus bħala mediċina attiva waħda f’obt.

factors associated with failure include high baseline viral load and obt that did not include at least one potent active agent.
fatturi assoċjati ma’ falliment jinkludu viral load b’linja bażi ta’ riferiment għoli u obt li ma kinetx tinkludi tal-anqas sustanza attiva qawwija waħda.